Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Packard BioScience

This article was originally published in The Gray Sheet

Executive Summary

Maker of instruments and related consumables for the life sciences research market, including drug discovery, genomics and biochip analysis, files for an initial public offering. Packard's primary products include microwell plate readers, imaging systems, automated liquid handling systems, laboratory robotics systems, bioanalytical spectrometers and biochemicals and related supplies. The IPO proceeds are tabbed for debt repayment, R&D and general corporate purposes. The Meriden, Connecticut firm recorded 1999 revenues of $264.9 mil., up 16.1%. A net loss of $198,000 compares to net income of $1.9 mil. in 1998. Underwriters include Merrill Lynch, Chase H&Q, and Robert Baird & Co

You may also be interested in...



Packard BioScience

Maker of instruments and related consumables for the life sciences research market, including drug discovery, genomics and biochip analysis, goes public April 20 via an initial offering of 12 mil. shares at $9 each and grosses $108 mil. The proceeds are tabbed for debt repayment, R&D, and general corporate purposes (1"The Gray Sheet" April 3, p. 22). Underwriters include Merrill Lynch, Chase H&Q, Robert Baird & Co., Banc of America Securities, and Thomas Weisel Partners

Corindus Envisions Network Of CorPath Robots For Remote Neurovascular And Coronary Interventions

The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.

UsernamePublicRestriction

Register

MT013201

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel